Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs.

Taylor T Schwartz¹, Hanke Zheng², Laetitia N'Dri², Sang Hee Park², Kristofer Norris³, Vardhaman A Patel², Scott B Robinson⁴, Keith Wittstock², Vadim Khaychuk², Alison R Silverstein⁴, Jeffrey A Sparks^5,6

¹Avalere Health, 1201 New York Ave. NW, Washington, DC, 20005, USA. taylor.schwartz@avalerehealth.com.

²Bristol Myers Squibb, Princeton, NJ, USA.

³Avalere Health, 1201 New York Ave. NW, Washington, DC, 20005, USA.

⁴Inovalon, Bowie, MD, USA.

⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.

⁶Harvard Medical School, Boston, MA, USA.

PubMed DOI

Abstract

INTRODUCTION: Persistence to therapy to treat rheumatoid arthritis (RA) is an indirect measure of tolerability and effectiveness in the real-world setting. Previous clinical trials suggested that seropositive patients with RA may particularly benefit from abatacept. The risk of non-persistence after initiating abatacept, tumor necrosis factor inhibitors (TNFi), and Janus kinase inhibitors (JAKi) a…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.